ArticleBone marrow transplantation2013

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.

A J Innes et al.PubMed ↗Publisher ↗

No numbers read from the abstract.